Protagonist Therapeutics Inc (PTGX)

Receivables turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	434,433	323,795	319,120	314,953	60,000	0	0	859	26,581	35,198	45,484	46,890	27,357	24,390	27,218	31,170	28,628	25,697	16,724	2,318
Receivables	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Receivables turnover		—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

December 31, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $434,433K ÷ $—K
= —

The receivables turnover ratio for Protagonist Therapeutics Inc shows that the company has not provided specific data for the calculation of this ratio from March 31, 2020, to December 31, 2024. Receivables turnover is a financial ratio that measures how efficiently a company is managing its accounts receivable by evaluating how many times a company collects its average accounts receivable during a specific period.

Given the absence of specific data points, it is not possible to analyze the trend or assess the efficiency of Protagonist Therapeutics Inc in collecting its outstanding receivables. This lack of information regarding receivables turnover hampers a comprehensive understanding of the company's liquidity management and operating efficiency in terms of accounts receivable turnover.

In order to perform a thorough examination of Protagonist Therapeutics Inc's receivables turnover and its implications for the company's financial health, it would be essential to access the actual receivables data for the periods in question.